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Background: Dysregulation of receptor tyrosine kinase MET by various mechanisms occurs in 3%e4% of non-small-cell
lung cancer (NSCLC) and is associated with unfavorable prognosis. While MET is a validated drug target in lung cancer,
the best biomarker strategy for the enrichment of a susceptible patient population still remains to be defined. Towards
this end we analyze here primary data from a phase I dose expansion study of the MET inhibitor capmatinib in patients
with advanced MET-dysregulated NSCLC.
Patients and methods: Eligible patients [18 years; Eastern Cooperative Oncology Group (ECOG) performance status
2] with MET-dysregulated advanced NSCLC, defined as either (i) MET status by immunohistochemistry (MET IHC) 2þ
or 3þ or H-score 150, or MET/centromere ratio 2.0 or gene copy number (GCN) 5, or (ii) epidermal growth factor
receptor wild-type (EGFRwt) and centrally assessed MET IHC 3þ, received capmatinib at the recommended dose of 400
mg (tablets) or 600 mg (capsules) b.i.d. The primary objective was to determine safety and tolerability; the key
secondary objective was to explore antitumor activity. The exploratory end point was the correlation of clinical
activity with different biomarker formats.
Results: Of 55 patients with advanced MET-dysregulated NSCLC, 40/55 (73%) had received two or more prior systemic
therapies. All patients discontinued treatment, primarily due to disease progression (69.1%). The median treatment
duration was 10.4 weeks. The overall response rate per RECIST was 20% (95% confidence interval, 10.4e33.0). In
patients with MET GCN 6 (n ¼ 15), the overall response rate by both the investigator and central assessments
was 47%. The median progression-free survival per investigator for patients with MET GCN 6 was 9.3 months
(95% confidence interval, 3.8e11.9). Tumor responses were observed in all four patients with METex14. The most
common toxicities were nausea (42%), peripheral edema (33%), and vomiting (31%).
Conclusions: MET GCN 6 and/or METex14 are suited to predict clinical activity of capmatinib in patients with NSCLC
(NCT01324479).
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Aberrant signaling through the MET receptor tyrosine ki-
nase is frequently encountered over a wide range of ma-
lignancies. Increased MET kinase activity triggers a highly
diverse set of signaling cascades, resulting in pleiotropic
effects on tumor cells, including survival, proliferation,
metastasis, and drug resistance. Several mechanisms havehttps://doi.org/10.1016/j.annonc.2020.03.293 1
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rantly activated in cancer. In epidermal growth factor re-
ceptor (EGFR) wild-type (wt) non-small-cell lung cancer
(NSCLC), sporadic MET gene copy gain is detected in about
1%e4% of newly diagnosed cases.1e3 MET amplification is
also implicated in acquired resistance to EGFR tyrosine ki-
nase inhibitors (TKIs), reported in 5%e26% of cases,
regardless of the presence of the T790M mutation.4e10
Genetic mutation is another way in which the MET
pathway can be activated. Among them, mutations dis-
rupting splice acceptor or donor sites leading to skipping of
MET exon 14 that encodes the CBL binding site were
identified in primary resected NSCLC. These genomic events
result in a functionally activated MET receptor through
stabilization and delayed internalization.11,12 Such splice site
alterations involving exon 14 (METex14) are detected in up
to 3% of NSCLC.13e18
Capmatinib (INC280) is a highly potent MET inhibitor in
biochemical (IC50 0.13 nM) and cellular assays across a
range of tumor types, including NSCLC, that also causes
regression of MET-dependent (amplified/autocrine) tumor
models in animals at well-tolerated doses.19 Capmatinib has
been demonstrated to be highly selective versus other ki-
nases in large panels of biochemical and binding assays.19 In
the completed dose-escalation part of this phase I study,
the recommended phase II dose (RP2D) of capmatinib was
established as 400 mg twice daily (b.i.d.) in tablet formu-
lation or 600 mg b.i.d. in capsule formulation. The current
established dose of capmatinib is 400 mg b.i.d. in tablet
formulation. Efficacy was reported from expansion groups
evaluating capmatinib in patients with advanced solid tu-
mors.20,21 We report here on the efficacy and safety of
capmatinib, and the definition of clinically applicable pre-
dictive biomarkers in patients with advanced MET-
dysregulated NSCLC treated at the RP2D in two dedicated
expansion groups.
METHODS
Study design and treatment
In the expansion phase, patients with solid tumors, including
an original NSCLC expansion group, were enrolled based on
MET dysregulation. The initial expansion group enrolled
patients with either local or central assessment of MET
dysregulation, including MET overexpression and amplifica-
tion, at the 600 mg b.i.d. capsule dose. An additional group
of patients was added to enroll patients with EGFRwt NSCLC
with high MET status by immunohistochemistry (MET IHC
3þ) as determined by a central laboratory at the 400 mg
b.i.d. tablet dose. Patient selection criteria by MET status
were further refined by post hoc analyses of genomic ab-
errations [MET gene copy number (GCN) gain and amplifi-
cation by FISH and MET mutation by next-generation
sequencing (NGS)], where sufficient tumor sample was
available. The primary objective of the study, completed in
the dose-escalation part (part 1), was to determine the
maximum tolerated dose (MTD)/RP2D of single-agent oral
capmatinib [based on the incidence, frequency, and category2 https://doi.org/10.1016/j.annonc.2020.03.293of dose-limiting toxicities (in cycle 1) and adverse events
(AEs)]. The key secondary end point was overall response
rate (ORR) per RECIST (by investigator assessment). The key
secondary objective in this second, expansion part (part 2) of
the study reported here, was to explore the antitumor ac-
tivity of capmatinib in patients with MET-dependent NSCLC.
Additional information is provided in supplementary
Appendix, available at Annals of Oncology online.
Patients
This study enrolled adult patients (aged 18 years) with
advanced (stage IIIB or IV, any histology) NSCLC refractory to
currently available therapies or for which no effective treat-
ment is available. Molecular biomarker status criteria in the
original NSCLC dose expansion group were MET H-score
150 or a ratio ofMET/centromere2.0, orMETGCN5, or
50% of tumor cells with IHC score 2þ or 3þ determined
either locally or centrally. In the additional NSCLC expansion
group, molecular biomarker status criteria were MET IHC 3þ
expression in 50% of tumor cells determined centrally and
documented EGFRwt status. MET expression levels were
determined by anti-total c-MET (SP44) rabbit monoclonal
antibody (Ventana Medical Systems, Tuscon, AZ, #790-4430).
Retrospective central analyses were carried out to determine
MET gene copy gain or amplification (FISH) and mutation
(NGS) in all patients with available tumor samples. NGS
analysis, carried out using the Foundation Medicine®, Cam-
bridge,MA T7 panel, interrogated 395 genes aswell as introns
of 31 genes involved in rearrangements. No more than three
lines of prior therapy were allowed in the EGFRwt MET IHC
3þ NSCLC expansion group (unless accepted following dis-
cussion with the study sponsor). Other key inclusion criteria
were one or more measurable lesions per RECIST v1.1 in the
EGFRwt MET IHC 3þ NSCLC expansion group and Eastern
Cooperative Oncology Group (ECOG) performance status2.
Exclusion criteria are included in the supplementary
Appendix, available at Annals of Oncology online.
Clinical assessments
Tumor lesions were assessed (investigator-confirmed) using
computed tomography unless contraindicated, in which
case magnetic resonance imaging with contrast was carried
out. Additional information is provided in supplementary
Appendix, available at Annals of Oncology online.
Statistical analysis
The data cut-off date for this report was 17 July 2017, when
all patients had discontinued. No formal statistical hypoth-
esis was tested. Additional information is provided in
supplementary Appendix, available at Annals of Oncology
online.
RESULTS
Patient characteristics and disposition
At the primary analysis cut-off date of 17 July 2017, a total
of 55 patients with NSCLC were enrolled: 26 patients wereVolume xxx - Issue xxx - 2020
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from the EGFRwt MET IHC 3þ group (supplementary
Figure S1, available at Annals of Oncology online). All of
the 26 patients in the original expansion group received
capsules, and of these, seven patients subsequently
switched to tablets. In the EGFRwt MET IHC 3þ group, all
patients received tablets.
Baseline demographics and disease characteristics are
presented in Table 1. The majority of patients were white
(73%), had stage IV disease (76%) at initial diagnosis,
adenocarcinoma histology (89%), and an ECOG perfor-
mance status of 1 (96%). Overall, 52 patients (95%) had
received one or more prior antineoplastic regimens, with 20
patients (36%) receiving three or more regimens. In total,
21 patients (38%) presented with controlled brain metas-
tases at study entry.
At the data cut-off date, all patients had discontinued
treatment, with disease progression [38 patients (69%)]
being the primary reason, followed by AEs [11 patients
(20%)], withdrawal of consent [four patients (7%)], lost to
follow-up [one patient (2%)], and because of transfer to
rollover study [one patient (2%)].Efficacy
Overall, a complete response (CR) by RECIST was reported
in 1/55 assessable patients and partial responses (PRs) were
observed in 10/55 assessable patients (ORR 20%) perTable 1. Patient demographics and disease characteristics
Characteristic/demographic NSCLC original
expansion group
N [ 26
Age, years, median (range) 60 (29e81)
Sex, male, n (%) 13 (50)
Race, n (%)
White 20 (77)
Asian 6 (23)
ECOG PS, n (%)
0 15 (58)
1 10 (38)
2 1 (4)
Prior systemic therapy, n (%) 25 (96)
0 1 (4)
1 5 (19)
2 6 (23)
3 14 (54)
Histology, n (%)
Adenocarcinoma 21 (81)
Large-cell carcinoma 1 (4)
Mucinous adenocarcinoma 1 (4)
Squamous cell carcinoma 2 (8)
EGFR, n (%)
Wild-type 20 (77)
Mutant 1 (4)
Unknown 5 (19)
ALK, n (%)
Negative 22 (85)
Unknown 4 (15)
Brain metastases at baseline, n (%) 11 (42)
ALK, anaplastic lymphoma kinase; ECOG PS, Eastern Cooperative Oncology Group perform
tochemistry; NSCLC, non-small-cell lung cancer.
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assessment in the original expansion group was 19% [95%
confidence interval (CI) 6.6e39.4] with five PRs. The ORR
was 21% (95% CI 8e39.7) with one CR and five PRs in the
EGFRwt MET IHC 3þ NSCLC patient group. Overall 38/55
patients experienced some reduction in tumor size as best
response, and 6/55 patients had a percentage change in
target lesion contradicted by overall lesion response
equivalent to progressive disease (Figure 1). The median
duration of response for responders is shown in Figure 2.
Combined analysis of all assessable patients (n ¼ 37)
with MET IHC 3þ NSCLC revealed one CR and eight PRs
(ORR 24%; Table 2, Figure 1) per investigator assessment.
Assessable patients (n ¼ 15) with MET GCN 6 (24% also
had MET IHC 3þ expression) reported one CR and six PRs
(ORR 47%; Table 2, Figure 1) per investigator assessment.
There were 41 NSCLC patients with available MET/CEP7
ratios; of these, nine were reported to have MET/CEP7 ratio
of 2.0 and the other 32 patients had MET/CEP7 ratio
<2.0. In the nine patients with MET/CEP7 ratio of 2.0, one
CR and two PRs were reported per investigator assessment.
Of the 46 NSCLC patients with available H-score, 17 patients
had reported H-score equal to 300, 25 patients had H-score
150 to <300, and the remaining four patients had H-score
<150. Based on investigator assessment, 4/17 patients with
H-score of 300 had a best overall response of CR or PR (one
CR and three PRs); 4/25 patients with H-score of 150 and
<300 had a best overall response of PR (Table 2). ResponseNSCLC EGFRwt
MET IHC3D expansion group
N [ 29
All NSCLC patients in
both expansion groups
N [ 55
61 (44e84) 60 (29e84)
20 (69) 33 (60)
20 (69) 40 (73)
9 (31) 15 (27)
4 (14) 19 (35)
24 (83) 34 (62)
1 (3) 2 (3)
27 (93) 52 (95)
2 (7) 3 (5)
15 (52) 12 (22)
6 (21) 20 (36)
6 (21) 20 (36)
28 (97) 49 (89)
0 1 (2)
0 1 (2)
0 2 (4)
29 (100) 49 (89)
0 1 (2)
0 5 (9)
29 (100) 51 (93)
0 4 (7)
10 (35) 21 (38)
ance status; EGFRwt, epidermal growth factor receptor wild-type; IHC, immunohis-
https://doi.org/10.1016/j.annonc.2020.03.293 3
Table 2. Best overall response by MET status treatment group per investigator and BIRC assessment
Investigator assessment MET IHC
N [ 54
MET GCN
N [ 44
MET/CEP7 ratio
N [ 41
MET H-score
N [ 46
METex14
N ¼ 4
All patients
N [ 55
0/1þ
(n ¼ 3)
2þ
(n ¼ 14)
3þ
(n ¼ 37)
<4
(n ¼ 17)
4 and <6
(n ¼ 12)
6
(n ¼ 15)
2
(n ¼ 9)
<2
(n ¼ 32)
<150
(n ¼ 4)
150 and <300
(n ¼ 25)
¼300
(n ¼ 17)
Complete response 0 0 1 0 0 1 1 0 0 1 0 1 1
Partial response 0 2 8 0 2 6 2 5 1 3 4 2 10
Stable disease 2 1 14 8 4 5 3 13 2 8 7 1 17
Progressive disease 0 8 8 5 3 2 2 7 0 8 4 0 17
Unknown 1 3 6 4 3 1 1 7 1 5 2 0 10
Overall response
rate, n (%)
(95% CI)
0
(0.0e70.8)
2 (14)
(1.8e42.8)
9 (24)
(11.8e41.2)
0
(0.0e19.5)
2 (17)
(2.1e48.4)
7 (47)
(21.3e73.4)
3 (33)
(7.5e70.1)
5 (16)
(5.3e32.8)
1 (25)
(0.6e80.6)
4 (16)
(4.5e36.1)
4 (24)
(6.8e49.9)
3 (75)
(19.4e99.4)
11 (20)
(10.4e33.0)
Disease control
rate, n (%)
(95% CI)
2 (67)
(9.4e99.2)
3 (21)
(4.7e50.8)
23 (62)
(44.8e77.5)
8 (47)
(23.0e72.2)
6 (50)
(21.1e78.9)
12 (80)
(51.9e95.7)
6 (67)
(29.9e92.5)
18 (56)
(37.7e73.6)
3 (75)
(19.4e99.4)
12 (48)
(27.8e68.7)
11 (65)
(38.3e85.8)
4 (100.0)
(39.8e100.0)
28 (51)
(37.1e64.6)
BIRC assessment MET IHC
N [ 54
MET GCN
N [ 44
MET/CEP7 ratio
N [ 41
MET H-score
N [ 46
METex14
N ¼ 4
All patients
N [ 55
0/1þ
(n ¼ 3)
2þ
(n ¼ 14)
3þ
(n ¼ 37)
<4
(n ¼ 17)
4 and <6
(n ¼ 12)
6
(n ¼ 15)
2
(n ¼ 9)
<2
(n ¼ 32)
<150
(n ¼ 4)
150 and <300
(n ¼ 25)
¼300
(n ¼ 17)
Complete response 0 0 1 0 0 1 1 0 0 1 0 1 1
Partial response 0 2 9 1 3 6 3 7 0 3 7 2 11
Stable disease 1 2 13 7 2 5 2 10 2 7 4 1 16
Progressive disease 1 6 7 5 3 2 2 7 1 8 2 0 15
Unknown 1 4 7 4 4 1 1 8 1 6 4 0 12
Overall response
rate, n (%)
(95% CI)
0
(0.0e70.8)
2 (14)
(1.8e42.8)
10 (27)
(13.8e44.1)
1 (6)
(0.1e28.7)
3 (25)
(5.5e57.2)
7 (47)
(21.3e73.4)
4 (44)
(13.7e78.8)
7 (22)
(9.3e40.0)
0
(0.0e60.2)
4 (16)
(4.5e36.1)
7 (41)
(18.4e67.1)
3 (75)
(19.4e99.4)
12 (22)
(11.8e35.0)
Disease control
rate, n (%)
(95% CI)
1 (33)
(0.8e90.6)
4 (29)
(8.4e58.1)
23 (62)
(44.8e77.5)
8 (47)
(23.0e72.2)
5 (42)
(15.2e72.3)
12 (80)
(51.9e95.7)
6 (67)
(29.9e92.5)
17 (53)
(34.7e70.9)
2 (50)
(6.8e93.2)
11 (44)
(24.4e65.1)
11 (65)
(38.3e85.8)
4 (100.0)
(39.8e100.0)
28 (51)
(37.1e64.6)
BIRC, blinded independent review committee; CI, confidence interval; GCN, gene copy number; IHC, immunohistochemistry.
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Figure 1. Best percentage change from baseline in sum of longest diameters in all NSCLC patients from both expansion groups.
MET IHC scores and MET GCN status are shown using different colors in the waterfall plot (investigator assessment, full analysis set; data cut-off 17 July 2017). A total of
17 patients had no evaluable responses due to lack of post-baseline tumor assessment or percentage change in target lesion contradicted by overall lesion response at
the time of data cut-off. n is the total number of events included in the analysis; N is the total number of patients included in the analysis.
CR, complete response; GCN, gene copy number; IHC, immunohistochemistry; NSCLC, non-small-cell lung cancer; PD, progressive disease; PR, partial response; SD,
stable disease; UN, unknown.
M. Schuler et al. Annals of Oncologyrates were consistent between the investigator assessment
and blinded independent review committee (BIRC) assess-
ment (Table 2 and supplementary Table S1, available at
Annals of Oncology online).Number of patients still at risk
IHC 3+
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Figure 2. Duration of response per BIRC assessed by RECIST v1.1 by group, GCN s
BIRC, blinded independent review committee; EGFRwt, epidermal growth factor rec
estimable; NSCLC, non-small-cell lung cancer; RECIST, Response Evaluation Criteria in
Volume xxx - Issue xxx - 2020The median progression-free survival (PFS) for all patients
(n ¼ 55) with NSCLC in both expansion groups was 3.7
months (95% CI 1.8e7.3, 80% PFS events) per investigator
assessment (RECISTv1.1) and 3.7 months (95% CI 1.9e7.4,18 21 24 27 30 33 36 39 42 45
2 1 0 0 0 0 0 0 0
1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 0
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0
0
0
0
Time (months)
Kaplan–Meier medians
NSCLC EGFRwt: 5.88 months
NSCLC original expansion: NE
GCN ≥6: 9.23 months
IHC 3+: 5.88 months
tatus ‡6 and IHC 3D for NSCLC patients using KaplaneMeier method.
eptor wild-type; GCN, gene copy number; IHC, immunohistochemistry; NE, not
Solid Tumors.
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Figure 3. Venn diagram showing overlap of MET IHC 3D, GCN ‡6, H-score [ 300, and MET/CEP7 ‡2.
GCN, gene copy number; IHC, immunohistochemistry.
Annals of Oncology M. Schuler et al.67% PFS events) per BIRC, assessed by RECISTv1.1. The
median PFS in the original NSCLC expansion group (N ¼ 26)
was 2.0 months (95% CI 1.6e7.4, 73% PFS events) versus
5.1 months (95% CI 1.9e7.9, 62% PFS events) in the EGFRwt
MET IHC 3þ group (N ¼ 29), assessed by BIRC. Across both
expansion groups (N ¼ 55), the median PFS for patients
with MET IHC 3þ tumors was 7.3 months (95% CI 3.0e8.2,
76% PFS events) per investigator assessment and 7.3
months (95% CI 3.5e8.1, 62% PFS events) per BIRC. The
median PFS for patients with MET GCN 6 (n ¼ 15) was 9.3
months (95% CI 3.8e11.9, 73% PFS events) per investigator
and 7.9 months (95% CI 3.6e12.8, 67% PFS events) per
BIRC. In patients with MET/CEP7 ratio of 2.0, median PFS
was 5.6 months (95% CI 1.0e11.0) per investigator
assessment. Among the patients with H-score of 150 to
<300 and 300, the median PFS by investigator assessment
was 3.0 months (95% CI 1.7e7.4) and 7.3 months (95% CI
1.8e9.2), respectively.
Supplementary Table S2, available at Annals of Oncology
online, depicts the biomarker profile by GCN and IHC status.
Overall, 13/55 patients (24%) had a GCN status 6 and IHC
status 3þ. Among 15 patients with GCN status 6, there
were eight patients who reported MET/CEP7 ratio of 2, of
which responses were observed in three patients. Further-
more, there were eight patients who had H-score of 3006 https://doi.org/10.1016/j.annonc.2020.03.293and GCN status 6. All patients with MET/CEP7 ratio of
2.0 also had IHC status 3þ. Overlaps between MET IHC,
GCN, MET/CEP7, and H-score are available in Figure 3.
There were 39 patients eligible for retrospective central
NGS panel analysis interrogating 395 cancer-related genes
as well as introns of 31 cancer-related genes, of which eight
patients had failed results. Among the 31 evaluable speci-
mens, four patients had METex14 (two each in the original
expansion group and EGFRwt MET IHC 3þ NSCLC patients
group) mutated NSCLC, all of whom showed tumor
shrinkage ranging from 14% to 83% (one CR, two PRs, one
stable disease) (Table 2; details of individual patients pro-
vided in supplementary Table S3, available at Annals of
Oncology online). Specific genomic alterations of four pa-
tients with METex14 were as follows: patient 1dmissense
D1010H, MET/CEP7 ratio was not recorded; patient
2dsplice site 3028þ1G>T, FISH MET/CEP7 ratio was 2.32,
FISH MET GCN was 13.8; patient 3dsplice site 2888_19/
2888_3del17, FISH MET/CEP7 ratio was 4.7, FISH MET GCN
was 13.6; and patient 4dmissense D1010N, FISH MET/CEP7
ratio was 4.40, FISH MET GCN was 11.2.
Safety
The median duration of exposure with capmatinib b.i.d.
dosing was 2.4 months (range, 0.03e43.01); 73% of theVolume xxx - Issue xxx - 2020
Table 3. Adverse events, regardless of causality (any grade occurring in
‡10% of patients and corresponding grades 3/4)
Preferred term All patients
N [ 55
All grades
n (%)
Grades 3/4
n (%)
Nausea 28 (60) 2 (4)
Peripheral edema 25 (46) 2 (4)
Vomiting 22 (40) 2 (4)
Decreased appetite 17 (31) 2 (4)
Fatigue 15 (27) 2 (4)
Dyspnea 14 (26) 2 (4)
Blood creatinine increased 13 (24) 0
Asthenia 11 (20) 2 (4)
Diarrhea 11 (20) 2 (4)
Back pain 10 (18) 1 (2)
Hypoalbuminemia 9 (16) 3 (6)
Alanine aminotransferase increase 8 (15) 3 (6)
Cough 8 (15) 0
Hypokalemia 8 (15) 3 (6)
Musculoskeletal pain 8 (15) 0
Pyrexia 8 (15) 0
Abdominal pain 7 (13) 2 (4)
Amylase increase 7 (13) 4 (7)
Headache 7 (13) 0
Pneumonia 7 (13) 4 (7)
Arthralgia 6 (11) 0
Aspartate aminotransferase increase 6 (11) 2 (4)
Constipation 6 (11) 1 (2)
Dizziness 6 (11) 0
Pruritus 6 (11) 0
Stomatitis 6 (11) 0
M. Schuler et al. Annals of Oncologypatients received >90% of the planned dose of capmatinib.
AEs requiring dose adjustment or interruption were re-
ported in 34/55 patients (62%), and 19 patients (35%)
required more than one dose reduction. AEs leading to
study drug discontinuation were reported in 11 patients
(20%). Treatment discontinuation due to suspected AEs
occurred in nine patients (16%).
All patients had one or more AEs during the study. The
most frequent AEs, regardless of causality and those sus-
pected as drug-related, are presented in Tables 3 and
supplementary Table S4, available at Annals of Oncology
online. The most frequent (occurring in >20% of patients)
study drug-related AEs that occurred at any grade were
nausea (42%), peripheral edema (33%), and vomiting (31%)
(Table 3). Grade 3/4 AEs, regardless of causality, occurred in
<10% of patients (Tables 3 and supplementary Table S4,
available at Annals of Oncology online). The most frequent
drug-related grade 3 or 4 AEs were nausea, peripheral
edema, and fatigue (all 4%; supplementary Table S3, avail-
able at Annals of Oncology online). Serious AEs, regardless
of study drug relationship, occurred in 30 patients (55%);
those with an incidence of 2% were pneumonia (7%),
pulmonary embolism (6%), pericardial effusion, abdominal
pain, nausea, vomiting, general physical health deteriora-
tion, increased blood creatinine, malignant pleural effusion,
tumor pain, and pleural effusion (4% each). Drug-related
serious AEs each occurred in eight patients (15%); pericar-
dial effusion, nausea, vomiting, malaise, hypersensitivity,
increased amylase, increased blood creatinine, cerebralVolume xxx - Issue xxx - 2020venous thrombosis, and headache (2%). Fourteen deaths
(26%) were reported in the expansion groups of NSCLC
patients. Six of these deaths were observed during survival
follow-up.DISCUSSION
In this dose-expansion part dedicated to NSCLC, capmatinib
demonstrated antitumor activity in pretreated patients with
advanced NSCLC with putative MET dependency. Prior
studies of MET targeting agents have suffered from
ambiguous biomarker criteria to select patients with high
likelihood of clinical benefit. Published data of different
biomarker prevalences in surgical series and samples from
patients with stage IV NSCLC have indicated that IHC-
measured expression of MET does not always correlate
with activated p-MET, and therefore, overexpression of MET
may not precisely reflect increased MET receptor activa-
tion.22,23 The phase II trial of onartuzumab plus erlotinib
showed promising results in patients with MET-positive
NSCLC, where MET status was determined using IHC
scoring (IHC 3þ, 2þ, 1þ, or 0; patients with 2þ or 3þ score
were considered MET-positive). However, onartuzumab plus
erlotinib was less effective than erlotinib plus placebo in
locally advanced or metastatic NSCLC, determined to be
MET-positive by IHC.24,25
Against this background, we made use of this uniformly
treated study population to systematically compare
different biomarkers and cut-off levels to inform the design
of pivotal studies of capmatinib in MET-positive NSCLC.
These included MET protein expression determined by IHC
(H-score and IHC status), MET GCN and gene amplification
assessed by FISH, and METmutations detected by NGS. The
strongest association with capmatinib benefit was found in
patients with MET GCN 6, which was present in 13/55
patients (24%). Almost half of these patients experienced
an objective response per RECIST with a median PFS of 9.3
months. Patient subgroups defined by MET IHC (H-score or
IHC status) and MET/CEP7 ratio exhibited much lower ORRs
and PFS times. Hence, despite considerable overlap be-
tween these different biomarker definitions, MET GCN 6
clearly emerged as clinically the most useful biomarker for
selection of NSCLC patients with high likelihood of benefit
from capmatinib. According to recent work by Guo et al.,26
MET IHC appears not to be predictive for METex14 muta-
tions or MET-amplification.
During the conduct of our study, METex14 mutations
emerged as novel recurrent genomic aberrations leading to
oncogenic MET receptor signaling. The resulting mutant MET
is stabilized through defective ubiquitination and internali-
zation, which adds another layer of activity over the pure
increase in genomic material. In a post hoc analysis, we
analyzed surplus tumor tissue from 39 study patients (31
assessable) by NGS for a panel of cancer-related genes. We
identified four cases with METex14 mutations, of which
three showed confirmed PR to capmatinib. These findings
confirm thatMETex14mutations serve as another biomarker
in addition to MET GCN 6 for patient selection inhttps://doi.org/10.1016/j.annonc.2020.03.293 7
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patients with recurrent or metastatic lung adenocarcinoma
analyzed by Memorial Sloan Kettering-Integrated Mutation
Profiling of Actionable Cancer Targets (MSK-IMPACT) assay,
MET splicing and amplification was observed in 3% and 1.4%
of patients, respectively. Clinical benefit with matched
treatment was observed in 13/17 patients (76.5%) with
METex14 alterations and one of two patients (50%) with
MET amplification.17 Crizotinib is an anaplastic lymphoma
kinase/ROS1/MET multi-targeted receptor TKI, which first
demonstrated antitumor activity (ORR of 32%) in patients
with advanced METex14 NSCLC.14 In the same study,
responses (ORR of 40%) to crizotinib were also observed in
patients with high MET amplification.27 Our data of capma-
tinib from this study clinically validate specific MET aberra-
tions as a targetable oncogenic dependency. Further
evaluation of the predictive value of different mechanisms of
MET dysregulation, including MET GCN gain and METex14
mutation, in patients with advanced NSCLC is being explored
prospectively in an ongoing phase II, seven-cohort study with
capmatinib, including treatment-naive patients (GEOMETRY
mono-1, NCT02414139), and promising efficacy data in
METex14-mutated NSCLC have been recently presented.28
Based on the current knowledge, METex14 is considered as
a strong molecular driver while evidence for MET is less
strong. Therefore, the contributory role of high amplification
to the efficacy of capmatinib in such cases cannot be fully
elucidated. However, based on the GEOMETRYmono-1 data,
the efficacy in METex14 seems to be independent from the
level of MET amplification. More specifically, in the GEOM-
ETRY mono-1 study, the duration of response was noted to
be independent of MET amplification (GCN <6 or 6)
determined by FISH, in the MET-mutated patients, with a P
value of 0.85 showing that the difference of duration of
response between MET-amplified (GCN 6) and non-
amplified (GCN <6) is not statistically different (data on
file). The findings of our study clearly argue for an indepen-
dent contribution of MET amplification (GCN 6) to
capmatinib activity in heavily pretreated NSCLC patients.
Capmatinib was well tolerated with an acceptable safety
profile in patients with advanced NSCLC. The most common
(25%) AEs, regardless of causality, were low-grade nausea,
peripheral edema, vomiting, decreased appetite, fatigue,
and dyspnea. Suspected drug-related peripheral edema
occurred in 33% of patients (majority were grade 1 or 2);
this adverse effect has been reported for other MET in-
hibitors,29,30 and may therefore be a potential drug class
effect not specific to capmatinib. Overall, capmatinib has an
acceptable safety profile. Even when combined with other
TKIs (gefitinib and nazartinib), it was well tolerated which
nominates capmatinib for further clinical exploration in
rationally designed combination therapies.31,32
In summary, capmatinib showed a clinically meaningful
rate of antitumor activity and acceptable safety profile in
pretreated advanced NSCLC patients with either MET GCN
6 and/or METex14 mutation. Overexpression alone
cannot be considered as a reliable biomarker to predict the
efficacy of capmatinib.8 https://doi.org/10.1016/j.annonc.2020.03.293ACKNOWLEDGEMENTS
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